Lates News

On August 13, Henry Pharmaceuticals (KBP) released a statement on its official website in response to a further ruling by the Singapore International Commercial Court (SICC). This ruling decided to maintain the interim injunction against KBP and its founder, Huang Zhenhua, to support the arbitration proceedings initiated by KBP and Novo Nordisk A/S respectively. The statement mentioned that KBP had initiated arbitration proceedings before Novo Nordisk. The validity of the injunction requested by Novo Nordisk will be determined in the arbitration proceedings following the SICC ruling. The SICC ruling reviewed a series of issues at the core of the dispute, including the conduct of clinical trials and the adequacy of due diligence. The conclusions of the SICC will be further examined by the arbitration tribunal. In this statement, Huang Zhenhua stated that KBP believes that Novo Nordisk's decision to terminate the development of Ocedurenone is wrong because the drug has the potential to benefit patients. KBP will prove this to the arbitration tribunal.